Kura Oncology (NASDAQ:KURA) Reaches New 52-Week Low – Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $6.79 and last traded at $7.33, with a volume of 1358259 shares. The stock had previously closed at $7.24.

Wall Street Analyst Weigh In

A number of research firms recently commented on KURA. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. UBS Group cut their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Bank of America dropped their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Stock Performance

The firm’s 50 day simple moving average is $7.92 and its 200-day simple moving average is $13.08. The company has a market capitalization of $587.90 million, a price-to-earnings ratio of -3.08 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

A number of institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new position in Kura Oncology in the fourth quarter worth approximately $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the fourth quarter valued at approximately $90,000. Corton Capital Inc. acquired a new position in Kura Oncology during the fourth quarter worth $99,000. Finally, Optimize Financial Inc bought a new stake in shares of Kura Oncology during the 4th quarter worth about $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.